Citation for published version (APA):
Reis Marques, T., Borgan, F., Ashok, A. H., Ureche-Angelescu, I., Meyers, J., Lingford-Hughes, A., Nutt, D., Veronese, M., Turkheimer, F. E., & Howes, O. (2020). GABA-A receptor differences in Schizophrenia: A Positron Emission Tomography study using [11C]Ro154513. Molecular Psychiatry, 0(0), 1-10. https://doi.org/10.1038/s41380-020-0711-y
GABA-A receptor differences in Schizophrenia: A Positron Emission Tomography study using $[^{11}C]$Ro154513

Tiago Reis Marques, MD, PhD$^{1,2}$, Abhishekh H Ashok, MD, PhD$^{1,2}$, Ilinca Angelescu, MSc$^2$, Faith Borgan, PhD$^{1,2}$, Jim Myers, PhD$^3$, Anne Lingford-Hughes, PhD$^4$; David J. Nutt, PhD$^4$; Mattia Veronese, PhD$^5$, Federico E. Turkheimer, PhD$^5$, Oliver D. Howes, MRCPsych, PhD$^{1,2}$

1 – Psychiatric Imaging Group, MRC London Institute of Medical Sciences (LMS), Imperial College London, London, United Kingdom
2 - Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
3 - Faculty of Medicine, Imperial College London, London, UK,
4 - Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Imperial College London, London
5 - Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom.

Correspondence to:

Tiago Reis Marques, MD, PhD
Psychiatric Imaging Group, MRC London Institute of Medical Sciences (LMS), Imperial College London, London, United Kingdom
Tel: +44 20 8383 3703
Email: t.dos-reis-marques@lms.mrc.ac.uk
Mailing Address: Hammersmith Hospital Campus, Du Cane Road, London W12 0NN

Abstract: 222 words
Text: 3806 words
Tables = 1
Figures = 4
ABSTRACT

A loss of GABA signaling is a prevailing hypothesis for the pathogenesis of schizophrenia. Preclinical studies indicate that blockade of the α5 sub-type of the GABA receptor (α5-GABA₅Rs) leads to behavioral phenotypes associated with schizophrenia, and post-mortem evidence indicates lower hippocampal α5-GABA₅Rs protein and mRNA levels in schizophrenia. However, it is unclear if α5-GABA₅Rs are altered in vivo or related to symptoms. We investigated α5-GABA₅Rs availability in in antipsychotic-free schizophrenia patients and antipsychotic-mediated schizophrenia patients using [¹¹C]Ro15-4513 PET imaging in a cross-sectional, case-control study design. Thirty-one schizophrenia patients (n=10 antipsychotic free) and twenty-nine matched healthy controls underwent a [¹¹C]Ro15-4513 PET scan and MRI. The α5 sub-type GABA-A receptor availability was indexed using [¹¹C]Ro15-4513 PET imaging. Dynamic PET data were analyzed using the two-tissue compartment model with an arterial plasma input function and total volume of distribution (VT) as the outcome measure. Symptom severity was assessed using the PANSS scale. There was significantly lower [¹¹C]Ro15-4513 VT in the hippocampus of antipsychotic-free patients, but not in medicated patients (p= 0.64), relative to healthy controls (p<0.05; Effect Size=1.4). There was also a significant positive correlation between [¹¹C]Ro15-4513 VT and total PANSS score in antipsychotic-free patients (r=.72; p=.044). The results suggest that antipsychotic-free patients with schizophrenia have lower α5-GABA₅Rs levels in the hippocampus, consistent with the hypothesis that GABA hypofunction underlies the pathophysiology of the disorder.
A leading hypothesis proposes that reduced gamma-aminobutyric acid (GABA) signaling in fronto-temporal brain regions underlies the pathogenesis of schizophrenia. This hypothesis is supported by post-mortem literature showing that schizophrenia patients relative to controls show lower mRNA and protein levels of the synthetic enzyme GAD67, lower levels of the GABA membrane transporter (GAT1), and lower expression and cell density of GABAergic interneurons relative to controls. In-vivo studies have reported a reduction in concentrations of GABA in cerebrospinal fluid (CSF) concentrations in first-episode psychotic patients. By contrast proton magnetic resonance spectroscopy (1H-MRS) have yielded discrepant findings, potentially due to the technical difficulties in accurately resolving GABA on MRS spectra and its complex relationship with synaptic GABA. GABA acts on two different subtypes of receptors, GABA-A and GABA-B. The GABA-A receptor is responsible for the majority of the physiological actions of GABA and it includes receptor subtypes made of different combinations of α, β, γ, δ, ε, r, π, and θ subunits, organized in a pentameric structure arranged around a central pore. The diversity in sub-unit composition and region-specific distribution allows GABA-A receptors to have distinct functional and physiological roles. Studies using [11C]flumazenil and [123I]iomazenil to index GABA receptor levels have not found differences between schizophrenia patients and healthy controls. However, these radiotracers are not GABA subtype-selective and show similar levels of uptake both in neocortex and limbic regions, which means they may be unable to detect differences in specific GABA receptor sub-types. In contrast, the inverse GABA-A receptor agonist [11C]Ro15-4513 is a radioligand that binds with 10 times higher affinity (~0.5nM) to the α5 subunit of the GABA receptor (α5-GABA<sub>AR</sub>) when compared to other subunits (~10nM). Although α5-GABA<sub>AR</sub> represents less than 5% of all GABA-A receptors, they are particularly concentrated in limbic regions. In the hippocampus, a key brain region implicated in the pathogenesis of schizophrenia, 25% of GABA-A receptors are α5-GABA<sub>AR</sub>. Importantly, changes in α5-GABA<sub>AR</sub> have been reported in schizophrenia patients, with post-mortem studies showing lower mRNA and protein levels of this receptor. Moreover, an α5-GABA<sub>AR</sub> positive allosteric modulator (PAM) has been shown
to reverse dopaminergic hyperactivation and behavioral sensitivity to psychostimulants in methylazoxymethanol (MAM) treated animals, a preclinical model that reproduces many phenotypes seen in schizophrenia.\textsuperscript{25} In contrast, the blockade of the α5-GABA\textsubscript{A}Rs impairs latent inhibition\textsuperscript{26} and reduces prepulse inhibition to startle,\textsuperscript{27} behavioral phenotypes associated with schizophrenia. Whilst these converging lines of evidence implicate the α5-GABA\textsubscript{A}Rs in schizophrenia, the only previous PET study using \textsuperscript{[11}C]Ro15-4513 to assess α5-GABA\textsubscript{A}Rs availability showed no differences in binding potential (BP) between patients with schizophrenia and controls.\textsuperscript{28} However, this study used a brain reference region approach, which is associated with an under-estimation of binding potentials, and the potential confound of systematic differences in GABA availability in the reference region as well.\textsuperscript{29} Therefore, it remains unclear if α5-GABA\textsubscript{A}Rs availability is altered in schizophrenia patients \textit{in-vivo} when controlling for these methodological issues.

In view of this, we sought to investigate α5-GABA\textsubscript{A}Rs availability in patients with schizophrenia using \textsuperscript{[11}C]Ro15-4513 PET imaging with an arterial input function. We hypothesized that both medicated and antipsychotic-free schizophrenia patients would have lower GABA-A receptor availability in the hippocampus when compared with healthy controls, and that GABA-A receptor availability would be associated with symptom severity.
MATERIAL AND METHODS

Participants

The study protocol was approved by the local Research Ethics Committee and the Administration of Radioactive Substances Advisory Committee, United Kingdom. All participants gave written informed consent prior to study participation. To control for potential sex differences in $\alpha_5$-GABA$_A$Rs availability$^{30}$ we specifically investigated male volunteers. Since antipsychotic medication may influence GABA function$^{31,32}$ we recruited two groups of patients, one taking antipsychotic treatment and the other antipsychotic free, and compared each group with matched healthy controls. Patients on antipsychotics were on a stable dose of antipsychotics for at least 4 weeks prior to the scan day. A total of 25 medicated patients with schizophrenia or schizoaffective disorder and 19 age matched healthy controls were recruited. A further group of 10 antipsychotic-free patients with schizophrenia or schizoaffective disorder and 10 age matched healthy controls were also recruited. All patients had capacity to give informed written consent and satisfied DSM-V diagnostic criteria for schizophrenia or schizoaffective disorder as determined by the Structured Clinical Interview of DSM-V-TR Axis I Disorders (SCID)$^{33}$. All subjects had a physical and psychiatric examination. Urinalysis was done on the day of the scan to exclude the use of illicit drugs. Exclusion criteria for all participants included: female sex; history of head trauma or injury with loss of consciousness longer than one hour; learning disabilities or lack of English fluency; current or lifetime history of alcohol dependence; current or lifetime history of substance abuse or dependence; use of any recreational substances within the last month; current use or within the last month of psychotropic medication (other than an antipsychotic) with possible effects on the GABA system (such as antiepileptic drugs, benzodiazepines and antidepressants)$^{34}$ and contraindications to MRI or PET. Patients were excluded if treated with clozapine, diagnosed with an organic psychosis or had a history of neurological or psychiatric disorders other than schizophrenia, as assessed by the Structured Clinical Interview for DSM-V-TR Axis I Disorders (SCID)$^{33}$. Exclusion criteria for the antipsychotic-free patients included current or recent use of antipsychotics within the last 4 weeks or five half-lives of the drug (whichever was longer). The antipsychotic-free status was confirmed by reviewing clinical notes and pharmacy records. Healthy controls were administered the
Psychosis Screening Questionnaire\textsuperscript{35} (PSQ) and were excluded if they reported any psychotic symptom, history of psychotic illness or family history of psychosis. None of the healthy controls recruited to the study had a positive score in any of the PSQ questions.

Four patients recruited into the study were excluded from participation due to PET contraindications (N=3) and commencement of clozapine treatment (N=1). Therefore, the final analyses include 21 patients on antipsychotic mediation (medicated group) and 19 matched healthy controls and 10 antipsychotic free patients (antipsychotic-free group) and 10 matched healthy controls.

**Clinical assessment**

Antipsychotic doses were converted to chlorpromazine equivalent dose as previously described.\textsuperscript{36} Symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS).\textsuperscript{37} Duration of untreated psychosis was quantified as the interval between first psychotic symptoms and first contact with psychiatric services.\textsuperscript{38}

**Neuroimaging evaluation**

**Image acquisition**

Participants were instructed to refrain from alcohol for at least 12 hours before scanning. Dynamic PET scans were acquired over 90 min using a Siemens ECAT EXACT HR. (CTI/Siemens, model 962; Knoxville, TN, USA) scanner, with 63 trans axial image planes covering an axial field of view of 15.5 cm. PET emission data were corrected for attenuation and scatter using a 10-min transmission scan and reconstructed using Fourier re-binning and 2D filtered back-projection with a 2.0mm kernel Ramp filter, into 23 dynamic frames (4 x 15, 4 x 60, 2 x 150, 10 x 300 and 3 x 600 seconds). The final reconstructed volume had voxel dimensions of 2.059 x 2.059 x 2.000mm\textsuperscript{3}.

During the PET acquisition, arterial blood data were sampled via the radial artery using a combined automatic-manual approach. A continuous sampling system (ABSS Allogg, Mariefred, Sweden) was employed to measure whole blood activity for first 15 minutes of each scan at the rate of one sample per second. Discrete blood samples were manually withdrawn at 2, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90 minutes, centrifuged and used to determine the plasma over blood activity ratio (POB). Samples
at 2, 5 and 10 minutes were used to calibrate the two sampling modalities. Samples taken at 2, 5, 10, 20, 30, 50, 70 and 90 minutes were also analysed using HPLC to calculate the plasma fraction of tracer free of metabolites (PPf). Both POB and PPf were fitted with an extended Hill model while whole blood TACs were fitted using a multi-exponential model using the Multiblood software. For each scan, a time delay was fitted and applied to the input functions (both parent and whole blood TACs) to account for the temporal delay between blood sample measurement and the target tissue data.

High resolution T1 weighted volumes were acquired using a 3T MR scanner (Magneton Trio Syngo MR B13 Siemens 3T; Siemens AG, Germany) and a magnetization prepared rapid gradient echo (MPRAGE) sequence (TR = 2300 ms, TE = 2.98 ms, TI = 900 ms, flip angle = 9°, field of view = 256 mm, image matrix = 240 x 256) with a resolution of 1 mm isotropic. For the volume, 160 abutting straight sagittal slices were collected in an interleaved right to the left manner, resulting in whole head coverage.

\[ ^{11} \text{C} \]Ro15-4513 PET data processing

Dynamic PET data were corrected for inter-frame motion and aligned with the individual’s structural T1 MR image by minimizing a mutual information cost function (SPM8, Wellcome Trust Center for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm). A neuroanatomical atlas was also co-registered to each subject’s image space (MIAKAT, http://www.imanova.co.uk) and applied to the dynamic PET data to derive regional time-activity curves (TACs). The hippocampus was selected as our a priori region of interest since it has been implicated in the pathogenesis of schizophrenia and has a high expression of α5 GABA-A receptors relative to the rest of the brain, representing approximately 25% of GABA-A receptors in this region. Moreover, the quantification of the α5 subunit using \[ ^{11} \text{C} \]Ro15-4513 has been shown to be particularly reliable in the hippocampus (ICC ~0.9). GABA-A receptor availability was indexed using the distribution volume (\( V_T \)) of \([^{11} \text{C}]{\text{Ro15-4513}}\). In agreement with previous publications, the \( V_T \) was calculated using with the metabolite-free arterial plasma input function and the two-tissue compartmental model (2TCM) solved with a non-linear least squares approach for the regional level and the Logan graphical method at the voxel level.
**Statistical analysis**

Statistical analyses were performed with SPSS version 20 (IBM, Armonk, N.Y.) for MAC OS X. The data distribution of all variables were tested using Kolmogorov-Smirnov tests and Grubbs test was used to determine if there were outlying data. Since all data were normally distributed, parametric tests were used. To test our primary hypothesis that GABA-A receptor availability would be altered in patients, an independent samples t-test was used to investigate if there were group differences in the $V_T$ of $[^{11}C]Ro15-4513$ in the hippocampus in 1) medicated patients relative to age-matched healthy controls and 2) antipsychotic-free patients relative to age-matched healthy volunteers. Independent samples t-tests were also used to investigate group differences in socio-demographic and clinical data. There was an outlier in the medicated patient group with high $V_T$ values in the hippocampus (Grubbs test p<0.05) and these data were excluded from further analysis. To determine whether there was an effect of group on $V_T$ values in our exploratory analyses of other brain regions we performed a two way-ANOVA with $V_T$ as the dependent variable and group (patient or control) and brain region as the independent variables. Exploratory analyses were also used to investigate the association between $[^{11}C]Ro15-4513$ and clinical data using Pearson’s product moment correlation. All data are presented as mean±SD, and the $\alpha$ level was set for all comparisons at $P<0.05$, corrected.
RESULTS

Demographic and Clinical Characteristics of Study Participants

Four groups of participants were included in the study: twenty-one patients taking antipsychotic mediation (medicated group) and 19 matched healthy controls and 10 antipsychotic free patients (antipsychotic-free group) and 10 matched healthy controls. In the medicated group, 19 patients had a diagnosis of schizophrenia and 2 patients had a diagnosis of schizoaffective disorder. No patient had any co-morbid psychiatric diagnosis as assessed by the SCID. Only one patient was taking a first-generation antipsychotic, while the remaining 20 patients were taking a second-generation antipsychotic drug (supplementary data, Table S1). All of the patients in the antipsychotic-free group had a diagnosis of schizophrenia and were antipsychotic-free for a period of at least 4 weeks or five half-lives of the drug (whichever was longer).

The demographic and clinical characteristics of the subjects are presented in Table 1. There were no group differences in any socio-demographic variables, or injected dose, injected mass or specific activity in medicated and antipsychotic-free patients and their respective healthy control groups.

Hippocampus α5-GABA_A Rs availability in patients and controls

There was significantly lower \([^{11}C]Ro15-4513 \text{ VT}\) in the hippocampus of antipsychotic-free patients when compared with healthy controls (mean ± SD: 6.90 ± 0.56 vs. 7.68 ± 0.54 respectively, \(p= 0.006\), Effect Size=1.4; figures 1 and 2).

In contrast there was no significant group difference in the \([^{11}C]Ro15-4513 \text{ VT}\) between the medicated patients and healthy controls (mean ± SD: 6.94 ± 0.62 vs. 7.06 ± 0.86, \(p= 0.64\)) (Fig. 3). There was also no significant difference in α5-GABA_A Rs availability between the medicated and antipsychotic-free schizophrenia groups (\(p=0.54\)).

Correlations between hippocampus α5-GABA_A Rs availability and clinical characteristics

We found no significant correlation between \([^{11}C]Ro15-4513 \text{ VT}\) and the exposure to antipsychotics, as measured in chlorpromazine equivalents doses (\(r=.32; \ p=.22\)). There was also no significant correlation with \(\text{VT}\) and duration of illness in either the antipsychotic-free (\(r=.105; \ p=.78\)) or the medicated (\(r=\)
groups. In the antipsychotic-free patient group, there was a significant positive correlation between $[^{11}C]Ro15-4513$ $V_T$ and severity of symptoms, as assessed by the total PANSS score ($r=.72; p=.044$) (figure 4), which was not significant in the medicated patient group ($r=.22; p=.38$). There was also no significant correlation between $[^{11}C]Ro15-4513$ $V_T$ and age in either the medicated ($r=-.20; p=.19$) or the antipsychotic-free ($r=.16; p=.49$) groups.

**Hippocampus volume**

There were no significant differences in hippocampal volumes between antipsychotic-free patients relative to healthy controls and between medicated patients and healthy controls (Table 1). There were also no significant correlations between hippocampal volumes and the $[^{11}C]Ro15-4513$ $V_T$ in the hippocampus in either antipsychotic-free patients ($r=-.035; p=.92$) or medicated patients ($r=1.99; p=.38$).

**Other brain regions**

In antipsychotic-free patients relative to healthy controls, there was a significant main effect of group on $V_T$ measures across all ROIs ($F (1, 144) = 5.73, p=0.01$). There was also a significant main effect of region on $V_T$ measures across all ROIs ($F (7, 144) = 179, p<0.001$). However, the group x region interaction was not significant ($F (7, 144) = 0.61, p=0.74$), and there were no significant differences in the post-hoc pair-wise comparisons for individual regions (supplementary data, Table S2). In the medicated patient group, there was no significant effect of group on $V_T$ measures across all ROIs ($F (1, 304) = 0.50, p=0.47$). However, there was a significant main effect of region on $V_T$ across the brain ($F (7, 304) = 161, P<0.001$) but the group x region interaction was not significant ($F (7, 304) = 0.94, p=0.47$), and there were no significant differences in the post-hoc pair-wise comparisons for individual regions (supplementary data, Table S2).
DISCUSSION

Our results show that GABA-A receptor availability, measured with a tracer selective for the α5-GABA-A receptor subunit, is significantly lower in the hippocampi of antipsychotic-free schizophrenia patients, and directly correlated with symptom severity. However, α5-GABA_A Rs availability is not significantly altered in antipsychotic-treated patients when compared to controls.

Our results extend post-mortem findings showing lower mRNA and protein levels of α5-GABA_A Rs in schizophrenia patients\textsuperscript{23,24} to show evidence for lower hippocampal uptake of an α5-GABA_A Rs selective tracer \textit{in vivo} in untreated patients with schizophrenia. However, our results are not consistent with the only previous \textsuperscript{11}C]Ro15-4513 PET study in schizophrenia patients,\textsuperscript{28} where no differences in \textsuperscript{11}C]Ro15-4513 binding potential (BP) were observed between antipsychotic-free patients and healthy controls. The lack of group effects in this previous study may be due to the use of simplified reference tissue model (SRTM) with the pons as the reference tissue to quantify \textsuperscript{11}C]Ro15-4513 binding potential. This approach relies on a number of assumptions which can easily lead to biased estimates if violated.\textsuperscript{46} Moreover, the intra-class correlation coefficients (ICC) across brain regions range between 0.35–0.80 when using SRTM, which indicates lower reliability than the approach we used, where ICC values are >0.82.\textsuperscript{42,47} The use of the pons as a reference region for \textsuperscript{11}C]Ro15-4513 PET has also been subject to criticism, since it may lead to the under-estimation of target binding.\textsuperscript{19,46,47} For these reasons, the SRTM approach used in the Asai et al. study may have lacked sensitivity to detect group differences.

Interestingly, our study showed no significant differences in \textsuperscript{11}C]Ro15-4513 V_T in medicated schizophrenia patients when compared with controls. Taken with our findings in the antipsychotic-free patients and other findings of lower GABA-A receptor prior to treatment,\textsuperscript{48} these results could suggest that there has been a normalization of α5-GABA_A Rs levels with antipsychotic treatment. In addition, reduced GABA release, as assessed using a tiagabine challenge, was seen in antipsychotic-naive individuals but not in antipsychotic treated patients.\textsuperscript{15} Previous literature has also shown evidence of altered GABA levels using 1H-MRS in un-medicated patients but not in medicated patients.\textsuperscript{32} Moreover, 4 weeks of exposure to antipsychotic treatment has also been found to normalize GABA levels in patients.\textsuperscript{32} Post-mortem studies also find differences between treated and untreated patients.
with schizophrenia, showing a positive correlation between the density of GAD and antipsychotic dose and higher expression levels of GAD67 and GABA-A protein subunits in antipsychotic treated patients relative to unmedicated patients.\(^9\) However, it is important to note that both in our study and on these prior studies, the antipsychotic treated group had a longer duration of illness than the untreated group. As such, it is not possible to disentangle duration of illness from treatment effects. However, in our study we found no significant associations between \(\alpha_5\)-GABA\(_A\)Rs availability and duration of illness, indicating that antipsychotic treatment could contribute to the lack of group differences in the treated patients. This is supported by preclinical findings showing an increased expression of GAD67 and increased GABA-A receptor binding in rats exposed to a range of different antipsychotics\(^50\) and for clinical studies showing that exposure to 4 weeks of antipsychotic treatment normalizes GABA levels in schizophrenia patients.\(^32\) However, longitudinal studies in patients are needed to test the hypothesis that there are changes in GABA-A receptor levels over time and if they are associated to exposure to antipsychotic medication.

**Strengths and limitations**

A strength of the study was that we included a large sample for a PET study and obtained arterial input functions.\(^{19}\) In our study we used the 2TCM model, which has been shown to have good reliability for \([^{11}C]Ro15\text{-}4513\) quantification (ICC ranging from 0.83–0.88), and \(V_T\) values derived from this model showing a close, linear relationship with \(\alpha_5\)-GABA\(_A\)Rs specific binding.\(^{19}\) One potential limitation on generalizability is that we only included males, as there are sex differences in GABA\(_A\) receptor expression.\(^{30}\) Future studies are needed to test if our findings generalize to female patients as well. Although both groups are matched for age, there is a trend level difference in age between antipsychotic-free patients and healthy controls (p=0.06). Importantly, the \(V_T\) values in our healthy control cohorts are similar to the ones reported in other studies using \([^{11}C]Ro15\text{-}4513\) PET,\(^{51,52}\) indicating that our findings are not driven by abnormal values in our controls. Furthermore, \(\alpha_5\)GABAARs show developmental reductions, and, supporting this, in healthy volunteers there is an inverse relationship between age and \([^{11}C]Ro15\text{-}4513\) \(V_T\) values. The lack of group differences in the chronic patients taken with the lower \(V_T\) values could suggest disruption of the normal age-related
reductions in α5-GABAARs. The antipsychotic free period in the antipsychotic-free group was 4 weeks or over five half-lives (whichever was longer), and no antipsychotic taken in the medicated group has significant affinity for GABA-A receptors (all Ki values > 10,000), indicating that direct effects of antipsychotic drugs on GABA-A receptors are unlikely to explain our findings. We did not find any significant difference in hippocampal volume, suggesting that partial volume effects are unlikely to account for our group differences. Furthermore, although a reduction in hippocampus volume in schizophrenia is commonly reported, in our study there were no significant volumetric differences in hippocampal volume between patients and controls. This can be explained by the hippocampus being one of the brain areas with greater structural variability. Finally, [11C]Ro15-4513 is a highly selective α5-GABAARs PET radiotracer, with α5 representing around 60–70% of the specific binding in α5 rich regions, and its affinity for this subunit is approximately 10 to 20-fold greater than to other subtypes of the GABA-A receptor. However, it also demonstrates measurable in-vivo binding at the α1 to α4 and α6 receptor subtype. Overall, although the [11C]Ro15-4513 Vₜ reflects the net effect of the availability of these different GABA-A receptors, the 20-fold greater affinity of [11C]Ro15-4513 to α5-GABAARs and the enriched expression of α5-GABAARs in the hippocampus indicates the lower [11C]Ro15-4513 hippocampal availability is likely to predominantly reflect lower α5-GABAAR levels.

The interpretation of the findings and their implications for understanding schizophrenia

GABAergic neurotransmission in the hippocampus plays a fundamental role in inhibiting the neuronal activity of pyramidal glutamatergic cells, through the activation of post-synaptic GABA receptors. The hippocampus has a particularly high concentration of α5-GABAARs relative to other brain regions, constituting up to 25% of all GABA-A receptors in the hippocampus. Although other receptor subtypes are also present, α5 represents around 60–70% of the specific binding of [11C]Ro15-4513 in the hippocampus. While α1 and α2-GABAARs are located synaptically and involved in the phasic inhibition of pyramidal cells, α5-GABAARs are located mainly at extra-synaptic sites. At these sites, α5-GABAARs are predominantly involved in generating a tonic inhibitory current to regulate the excitability of pyramidal neurons and decrease network excitability. Interestingly, this tonic
inhibition has shown to be at least equally important in the regulation of pyramidal cells firing as phasic inhibition. α5-GABA \textsubscript{A}Rs deficient mice show reduced tonic inhibition resulting in hippocampus hyperexcitability, which can be reversed by pharmacologically increasing the tonic current. The lower α5-GABA \textsubscript{A} receptor levels we observe may therefore be contribute to reductions in tonic inhibition, leading to an increase in hippocampal hyperexcitability. This interpretation is supported by previous literature implicating the hippocampus in the pathophysiology of schizophrenia including changes in hippocampal volume as well as changes in regional cerebral blood flow and blood oxygen level-dependent (BOLD) signal. Taken together these suggest that lower α5-GABA \textsubscript{A}Rs levels could lead to a state of excessive excitation. The lower α5-GABA \textsubscript{A}Rs levels we observe may therefore be contributory factors in reducing tonic inhibition, leading to an increase in hippocampal hyperexcitability. This interpretation is supported by previous literature implicating the hippocampus in the pathophysiology of schizophrenia including changes in hippocampal volume as well as changes in regional cerebral blood flow and blood oxygen level-dependent (BOLD) signal. Taken together these suggest that lower α5-GABA \textsubscript{A}Rs levels could lead to a state of excessive excitation.

Our findings are therefore consistent with hypotheses that a reduction in GABAergic neurotransmission disinhibits glutamatergic pyramidal neurons, resulting in the loss of synchronous cortical activity, and subcortical dopamine dysregulation. Furthermore, the activation of α5-GABA \textsubscript{A}Rs by positive allosteric modulator (PAM) have shown to reverse the dopaminergic and behavioral abnormalities observed in the MAM model. These findings highlight the therapeutic potential of targeting GABA function in schizophrenia. We found a significant positive correlation between α5-GABA \textsubscript{A}Rs availability and symptom severity in antipsychotic-free patients. Whilst this supports a link between α5-GABA \textsubscript{A}Rs dysregulation and the clinical expression of the disorder, the direction of the association is not consistent with a simple model of α5-GABA \textsubscript{A}Rs hypofunction leading to hippocampal over-activity and symptoms. It was recently shown, using a viral-mediated gene transfer, that an increase in the expression of α5-GABA \textsubscript{A}Rs normalizes VTA dopamine cell population activity. Thus, one explanation that could account for both the lower RO-15 binding in patients and a positive correlation with symptoms, is that low α5-GABA \textsubscript{A}R levels are a vulnerability factor but that once the disorder develops there is a compensatory increase in α5-GABA \textsubscript{A}R levels in response to dysregulation of other systems. This is consistent with the role of α5-GABA \textsubscript{A}Rs in providing tonic regulation of pyramidal neurons. A longitudinal study is needed to test this model further. Finally, our exploratory analysis in other brain regions also showed a significant difference between antipsychotic-free patients and controls in the omnibus test, suggesting there may be GABA-A receptor alterations in other brain regions in schizophrenia. However, no individual region was significantly different in the pair-wise comparisons, which could reflect the fact that the expression of α5-GABA \textsubscript{A}Rs...
is lower in these regions.\textsuperscript{33}

**Conclusions and future directions**

This study provides evidence that antipsychotic-free patients with schizophrenia have lower GABA-A receptors in the hippocampus, predominantly of the alpha-5 subtype, that is not seen in antipsychotic treated patients. These findings are consistent with the hypothesis that GABA hypofunction underlies the pathophysiology of the disorder, and highlights the potential of GABA-ergic modulators as therapeutic targets for schizophrenia.
**Funding:** This study was funded by grants MC-A656-5QD30 from the Medical Research Council-UK, 666 from the Maudsley Charity 094849/Z/10/Z from the Brain and Behavior Research Foundation, and Wellcome Trust to Dr Howes.

**Conflicts of Interest / Disclosures:** Dr Reis Marques conducts research funded by the Medical Research Council (UK) and King’s College London. Dr Reis Marques have received honoraria for speaking and chairing engagements from Lundbeck, Janssen and Astellas. Prof Howes conducts research funded by the Medical Research Council (UK), the National Institute of Health Research (UK) and the Maudsley Charity. Prof Howes has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Astra-Zeneca, BMS, Eli Lilly, Jansenn, Lundbeck, Lyden-Delta, Servier, and Roche. Neither Prof Howes or his family have been employed by or have holdings/a financial stake in any biomedical company. ALH has received honoraria paid into her institutional funds for speaking and chairing engagements from Lundbeck, Lundbeck Institute UK, Janssen-Cilag, Pfizer, Servier; received research grants or support from Lundbeck, GSK; consulted by Silence, NET Device Corps, Sanofi-Aventis and also consulted by but received no monies from Britannia Pharmaceuticals, GLG, Opiant, Lightlake and Dobrin. Dr. Myers have received travel funds from Roche. Dr Veronese is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. Prof. Turkheimer, Dr. Ashok, Dr. Borgan and Miss Angelescu reports no financial relationships with commercial interests.
REFERENCES

1 - Coyle JT. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem Pharmacol. 2004 Oct 15;68(8):1507-14. Review.

2 - Grace AA. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology. 2012 Mar;62(3):1342-8. Review.

3 - Lewis, DA; Curley, AA; Glausier, JR; Volk, DW Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neurosciences. 2012;35(1):57-67.

4 - Curley AA, Arion D, Volk DW, Asafu-Adjei JK, Sampson AR, Fish KN, et al. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am J Psychiatry. 2011 Sep;168(9):921-9.

5 - Volk D, Austin M, Pierri J, Sampson A, Lewis D. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry. 2001 Feb;158(2):256-65.

6 - Sakai T, Oshima A, Nozaki Y, Ida I, Haga C, Akiyama H, et al. Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropathology. 2008 Apr;28(2):143-50.

7 - Orhan F, Fatouros-Bergman H, Goiny M, Malmqvist A, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, et al. CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Mol Psychiatry. 2018 May;23(5):1244-1250.

8 - Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014 Jan;19(1):20-9. Review.

9 - Egerton A, Modinos G, Ferrera D, McGuire P. Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis. Transl Psychiatry. 2017 Jun 6;7(6):e1147

10 - Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001 Nov;179:390-6. Review.

11 - Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci. 2004 Sep;27(9):569-75. Review.

12 - Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry. 1997 Jan;154(1):56-63.
13 - Abi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, Baldwin RM, et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology. 1999 Jun;20(6):650-61.

14 - Lee JS, Lee JD, Park HJ, Oh MK, Chun JW, Kim SJ, et al. Is the GABA System Related to the Social Competence Improvement Effect of Aripiprazole? An (18)F-Fluoroflumazenil PET Study. Psychiatry Investig. 2013 Mar;10(1):75-80.

15 - Frankle WG, Cho RY, Prasad KM, Mason NS, Paris J, Himes ML, et al. In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients. Am J Psychiatry. 2015

16 - Sieghart W. Structure and pharmacology of gamma-aminobutyric acid A receptor subtypes. Pharmacol Rev 1995; 47: 181–234.

17 - Hammers A. Flumazenil positron emission tomography and other ligands for functional imaging. Neuroimaging Clin N Am. 2004 Aug;14(3):537-51. Review.

18 - Lingford-Hughes A, Hume SP, Feeney A, Hirani E, Osman S, Cunningham VJ, et al. Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab. 2002 Jul;22(7):878-89.

19 - Myers JF, Comley RA, Gunn RN. Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans. J Cereb Blood Flow Metab. 2017 Jun;37(6):2137-2148.

20 - McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. 1996 Apr;19(4):139-43. Review.

21 - Sur C, Fresu L, Howell O, McKernan RM, Atack JR. Autoradiographic localization of alpha5 subunit-containing GABAA receptors in rat brain. Brain Res. 1999; 822:265–70.

22 - Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10164-9.

23 - Beneyto M, Abbott A, Hashimoto T, Lewis DA. Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cereb Cortex. 2011 May;21(5):999-1011.

24 - Duncan CE, Webster MJ, Rothmond DA, Bahn S, Elashoff M, Shannon Weickert C. Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res. 2010 Jul;44(10):673-81

25 - Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA. A novel alpha5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology. 2011; 36:1903–11.
26 - Gerdjikov TV, Rudolph U, Keist R, Mohler H, Feldon J, Yee BK. Hippocampal alpha 5 subunit-containing GABA A receptors are involved in the development of the latent inhibition effect. Neurobiol Learn Mem. 2008; 89:87–94.

27 - Hauser J, Rudolph U, Keist R, Mohler H, Feldon J, Yee BK. Hippocampal alpha5 subunit containing GABAA receptors modulate the expression of prepulse inhibition. Mol Psychiatry, 2005; 10:201–7.

28 - Asai Y, Takano A, Ito H, Okubo Y, Matsuura M, Otsuka A, et al. GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit. Schizophr Res. 2008 Feb;99(1-3):333-40.

29 - Veronese M, Zanotti-Fregonara P, Rizzo G, Bertoldo A, Innis RB, Turkheimer FE. Measuring specific receptor binding of a PET radioligand in human brain without pharmacological blockade: The genomic plot. Neuroimage. 2016 Apr 15;130:1-12.

30 - Bristow GC, Bostrom JA, Haroutunian V, Sodhi MS. Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. Schizophr Res. 2015 Sep;167(1-3):57-63.

31 - Tayoshi S, Nakataki M, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res (2010) 117(1):83–91

32 - de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, León-Ortiz P, Rodríguez-Mayoral O, Jung-Cook H, et al. Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients. Biol Psychiatry. 2018 Mar 15;83(6):475-483

33 - First, M., Spitzer, R., Miriam, G., & Williams, J. Structured Clinical Interview of DSM-IV-TR AXIS I Disorders-Patient Edition (SCID-I/P, 1/2007 revision). (Biometrics research, 2007).

34 - Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry. 2004 Feb;161(2):368-70.

35 - Bebbington PE, Nayani T. The Psychosis Screening Questionnaire. Int J Methods Psychiatr Res. 1995;5:11–20.

36 - Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64:663–667

37 - Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–276
38 - Polari A, Lavoie S, Sarrasin P, Pellanda V, Cotton S, Conus P. Duration of untreated psychosis: a proposition regarding treatment definition. Early Interv Psychiatry. 2011;5(4):301–308.

39 - Tonietto M, Rizzo G, Veronese M, Bertoldo A. Modelling arterial input functions in positron emission tomography dynamic studies. Conf Proc IEEE Eng Med Biol Soc. 2015;2015:2247-50.

40 - Tonietto M, Veronese M, Rizzo G, Zanotti-Fregonara P, Lohith TG, Fujita M, et al. Improved models for plasma radiometabolite correction and their impact on kinetic quantification in PET studies. J Cereb Blood Flow Metab. 2015 Sep;35(9):1462-9.

41 - Tonietto M, Rizzo G, Veronese M, Borgan F, Bloomfield P, Howes O, et al. A unified framework for plasma data modelling in dynamic Positron Emission Tomography studies. IEEE Trans Biomed Eng. 2018 Oct 9.

42 - McGinnity CJ, Riaño Barros DA, Rosso L, Veronese M, Rizzo G, Bertoldo A, et al. Test-retest reproducibility of quantitative binding measures of [11C]Ro15-4513, a PET ligand for GABAA receptors containing alpha5 subunits. Neuroimage. 2017 May 15;152:270-282.

43 - Horder J, Andersson M, Mendez MA, Singh N, Tangen Å, Lundberg J, et al. GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Sci Transl Med. 2018 Oct 3;10(461).

44 - Myers JF, Rosso L, Watson BJ, Wilson SJ, Kalk NJ, Clementi N, et al. Characterisation of the contribution of the GABA-benzodiazepine α1 receptor subtype to [(11)C]Ro15-4513 PET images. J Cereb Blood Flow Metab. 2012 Apr;32(4):731-44.

45 - Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000 Oct;27(7):661-70.

46 - Salinas CA, Searle GE, Gunn RN. The simplified reference tissue model: model assumption violations and their impact on binding potential. J Cereb Blood Flow Metab. 2015 Feb;35(2):304-11.

47 - Hammers A, Panagoda P, Heckemann RA, et al. [11C]Flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling? J Cerebr Blood Flow Metab 2008; 28: 207–216.

48 - Kang JJ, Park HJ, Kim SJ, Kim KR, Lee SY, Lee E, et al. Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study. Schizophr Bull. 2014 May;40(3):548-57.

49 - Steiner J, Brisch R, Schiltz K, Dobrowolny H, Mawrin C, Krzyżanowska M, et al. GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia: A post-mortem study. Schizophr Res. 2016 Nov;177(1-3):10-17

50 - Zink M, Schmitt A, May B, Müller B, Demirakca T, Braus DF, et al. Differential effects of long-term
treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr Res. 2004 Feb 1;66(2-3):151-7

51 - Mick I, Ramos AC, Myers J, Stokes PR, Chandrasekera S, Erritzoe D, et al. Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity. Addict Biol. 2017 Nov;22(6):1601-1609.

52 - Horder J, Andersson M, Mendez MA, Singh N, Tangen Å, Lundberg J, et al. GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Sci Transl Med. 2018 Oct 3;10(461).

53 - Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96.

54 - Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity. Addict Biol. 2017 Nov;22(6):1601-1609.

55 - Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96.

56 - Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.

57 - Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997 Jan;280(1):83-97.

58 - Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003 Aug;28(8):1400-11.

59 - Adriano F, Caltagirone C, Spalletta G. Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist. 2012;18(2):180–200.

60 - Brugger SP, Howes OD. Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis. JAMA Psychiatry. 2017 Nov 1;74(11):1104-1111.

61 - Freund TF, Buzsáki G. Interneurons of the hippocampus. Hippocampus. 1996;6(4):347-470. Review.

62 - Heckers S, Konradi C. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res. 2015 Sep;167(1-3):4-11. Review.

63 - Stefanits H, Milenkovic I, Mahr N, Pataraia E, Hainfellner JA, Kovacs GG, et al. GABAA receptor subunits in the human amygdala and hippocampus: Immunohistochemical distribution of 7 subunits. J Comp Neurol. 2018 Feb 1;526(2):324-348.

64 - Serwanski DR, Miralles CP, Christie SB, Mehta AK, Li X, De Blas AL. Synaptic and nonsynaptic localization of GABAA receptors containing the alpha5 subunit in the rat brain. J Comp Neurol. 2006 Nov 20;499(3):458-70.

65 - Kasugai Y, Swinny JD, Roberts JD, Dalezios Y, Fukazawa Y, Sieghart W, et al. Quantitative localisation of
synaptic and extrasynaptic GABAA receptor subunits on hippocampal pyramidal cells by freeze-fracture replica immunolabelling. Eur J Neurosci. 2010 Dec;32(11):1868-88.

64 - Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci. 2005 Mar; 6(3):215-29.

65 - Brickley SG, Mody I. Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron. 2012 Jan 12; 73(1):23-34.

66 - Caraiscos VB, Elliott EM, You-Ten KE, Cheng VY, Belelli D, Newell JG, et al. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3662-7.

67 - Glykys J, Mann EO, Mody I. Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J Neurosci. 2008 Feb 6;28(6):1421-6.

68 - Glykys J, Mody I. Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABA A receptor alpha5 subunit-deficient mice. J Neurophysiol. 2006 May;95(5):2796-807.

69 - Nakahara S, Matsumoto M, van Erp TGM. Hippocampal subregion abnormalities in schizophrenia: A systematic review of structural and physiological imaging studies. Neuropsychopharmacol Rep. 2018 Dec;38(4):156-166. Review.

70 - Talati P, Rane S, Kose S, Blackford JU, Gore J, Donahue MJ, et al. Increased hippocampal CA1 cerebral blood volume in schizophrenia. Neuroimage Clin. 2014 Jul 22;5:359-64

71 - Ongür D, Cullen TJ, Wolf DH, Rohan M, Barreira P, Zalesak M, et al. The neural basis of relational memory deficits in schizophrenia. Arch Gen Psychiatry. 2006 Apr;63(4):356-65.

72 - Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010 Feb;11(2):100-13. Review.

73 - Grace AA. Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotox Res. 2010 Nov;18(3-4):367-76. Review.

74 - Donegan JJ, Boley AM, Yamaguchi J, Toney GM, Lodge DJ. Modulation of extrasynaptic GABAA alpha 5 receptors in the ventral hippocampus normalizes physiological and behavioral deficits in a circuit specific manner. Nat Commun. 2019 Jun 27;10(1):2819.

75 - Schulz JM, Knoflach F, Hernandez MC, Bischofberger J. Dendrite-targeting interneurons control synaptic NMDA-receptor activation via nonlinear α5-GABAA receptors. Nat Commun. 2018 Sep 3;9(1):3576.